Graeme Quest
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Graeme Quest has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Alissa Palazzolo
Department of Clinical Laboratory Services, Kingston Health Sciences Centre
1 shared publication- Ashish Rajput
Pathology and Laboratory Medicine, Newfoundland Health Services, St John’s, NL A1B 3V6, Canada
1 shared publication - Benjamin Chin-Yee
Schulich School of Medicine and Dentistry, Western University, London, Canada
1 shared publication - Cheryl A. Mather
Molecular Pathology (North Sector), Alberta Precision Laboratories, Edmonton, AB T6G 2B7, Canada
1 shared publication - Darci T. Butcher
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada
1 shared publication - Doha Itani
Department of Pathology, Dalhousie University, Halifax, NS B3H 4R2, Canada
1 shared publication
Latest Publications
- Open Access
- 25 August 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 505
Charting the Future of Canadian Adult Acute Myeloid Leukemia (AML) Laboratory Testing: A Canadian Leukemia Study Group Current State Mapping of Diagnostic AML Laboratory Practice
Clinical decision making in Acute Myeloid Leukemia (AML) critically relies on rapid genomic characterization. To better understand the AML diagnostic landscape in Canada, the Canadian Leukemia Study Group (CLSG) conducted a survey of laboratory hematology leadership (n = 18) at 16 laboratories across 10 provinces, administered using Google Forms in September 2024. Nearly all surveyed sites were equipped to deliver a full suite of testing platforms through existing on-site infrastructure or laboratory partnerships. Reporting practices varied in terms of genomic integration into bone marrow results and the use of AML classification systems. Turn-around-time (TAT) targets were predominantly determined through internal institutional consensus (62%) or recommendations by provincial cancer agencies/international groups (44%). TAT reduction was a top priority for 56% of laboratories, suggesting timely biomarker results to be an active area for improvement. Various treatment-determining biomarkers were frequently assessed as rapid-tests (defined as a 5-day TAT), including FLT3-ITD (69%), FLT3-TKD (56%), and NPM1 (56%), while others such as IDH1 and TP53 were rapid at a limited number of laboratories. Respondents demonstrated a strong shared interest in joint projects such as the validation of AML measurable residual disease (MRD) assays (56%). There was also unanimous support for establishing CLSG AML laboratory consensus guidelines. This survey documents the current state of Canadian AML laboratories and provides a foundation for future shared development projects.
- 25 August 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 505
Open AccessCharting the Future of Canadian Adult Acute Myeloid Leukemia (AML) Laboratory Testing: A Canadian Leukemia Study Group Current State Mapping of Diagnostic AML Laboratory Practice
Clinical decision making in Acute Myeloid Leukemia (AML) critically relies on rapid genomic characterization. To better understand the AML diagnostic landscape in Canada, the Canadian Leukemia Study Group (CLSG) conducted a survey of laboratory hematology leadership (n = 18) at 16 laboratories across 10 provinces, administered using Google Forms in September 2024. Nearly all surveyed sites were equipped to deliver a full suite of testing platforms through existing on-site infrastructure or laboratory partnerships. Reporting practices varied in terms of genomic integration into bone marrow results and the use of AML classification systems. Turn-around-time (TAT) targets were predominantly determined through internal institutional consensus (62%) or recommendations by provincial cancer agencies/international groups (44%). TAT reduction was a top priority for 56% of laboratories, suggesting timely biomarker results to be an active area for improvement. Various treatment-determining biomarkers were frequently assessed as rapid-tests (defined as a 5-day TAT), including FLT3-ITD (69%), FLT3-TKD (56%), and NPM1 (56%), while others such as IDH1 and TP53 were rapid at a limited number of laboratories. Respondents demonstrated a strong shared interest in joint projects such as the validation of AML measurable residual disease (MRD) assays (56%). There was also unanimous support for establishing CLSG AML laboratory consensus guidelines. This survey documents the current state of Canadian AML laboratories and provides a foundation for future shared development projects.
- 15 April 2025
- Published by Springer Nature
- p. 39-55
Multiplex PCR for the Rapid Diagnosis of Myeloproliferative Neoplasms
Myeloproliferative neoplasms (MPN) develop as a disease of aging, due to the disruption of normal hematopoiesis, triggered by somatic mutations and a sustained inflammatory cycle. Driving variants within JAK2, MPL, and CALR are associated with various subtypes of MPN, with known targeted therapeutics and guided patient prognosis. Targeted clinical testing for the diagnosis of these precise driving variants within these key genes has an integral role for personalized medicine.
- 15 April 2025
- Published by Springer Nature
- p. 39-55
Multiplex PCR for the Rapid Diagnosis of Myeloproliferative Neoplasms
Myeloproliferative neoplasms (MPN) develop as a disease of aging, due to the disruption of normal hematopoiesis, triggered by somatic mutations and a sustained inflammatory cycle. Driving variants within JAK2, MPL, and CALR are associated with various subtypes of MPN, with known targeted therapeutics and guided patient prognosis. Targeted clinical testing for the diagnosis of these precise driving variants within these key genes has an integral role for personalized medicine.